Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma

doi:10.4251/wjgo.v17.i4.103631

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (57)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-6) series.

Item

Count

PDF

HTML

Tables (1-6)

Sum=54

Apr 15, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103631
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103631

Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma

Lu-Wen Liang, Rong-Hong Luo, Zhi-Li Huang, Li-Na Tang

Lu-Wen Liang, Infection and Liver Disease Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China

Rong-Hong Luo, Zhi-Li Huang, Li-Na Tang, Department of Infectious Diseases, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China

Author contributions: Liang LW and Tang LN designs research; Huang ZL conducts case collection; Luo RH guide the research.

Institutional review board statement: The research was reviewed and approved by the Review Committee of The Second Affiliated Hospital of Chongqing Medical University.

Informed consent statement: All research participants or their legal guardians provided written informed consent prior to study registration.

Conflict-of-interest statement: No conflict of interest is associated with this work.

Data sharing statement: No other data available.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Rong-Hong Luo, Professor, Department of Infectious Diseases, The Third Affiliated Hospital of Chongqing Medical University, No. 1 Shuanghu Branch Road, Yubei District, Chongqing 401120, China. loudiudiu2024@163.com

Received: November 26, 2024
Revised: December 25, 2024
Accepted: February 7, 2025
Published online: April 15, 2025
Processing time: 120 Days and 7.3 Hours

Core Tip

Core Tip: The combination therapy of cabozantinib and nivolumab in advanced hepatocellular carcinoma can upregulate T lymphocyte levels, reduce tumor marker levels, effectively prolong survival time, and has better efficacy than simple control treatment, with good safety.